Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis

Psoriasis

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Br J Dermatol.

Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group

doi: 10.1111/bjd.17036.

Psoriasis

Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics

Eur J Dermatol

Offidani A, Radi G, Bianchi L, Cannavò SP, Conti A, Gesuita R, Salaffi F, Talamonti M, Campanati A

doi: 10.1684/ejd.2021.4121

Psoriasis

Safety of Systemic Agents for the Treatment of Pediatric Psoriasis

JAMA Dermatol.

Bronckers IMGJ, Seyger MMB, West DP, Lara-Corrales I, Tollefson M, Tom WL, Hogeling M, Belazarian L, Zachariae C, Mahé E, Siegfried E, Philipp S, Szalai Z, Vleugels RA, Holland K, Murphy R, Baselga E, Cordoro K, Lambert J, Alexopoulos A, Mrowietz U, Kievit W, Paller AS; Psoriasis Investigator Group (PsIG) of the Pediatric Dermatology Research Alliance and the European Working Group on Pediatric Psoriasis (EWGPP)

doi: 10.1001/

Further Publications Rheumatology

Psoriatic arthritis incidence among patients receiving biologic medications for psoriasis: A nested case control study

Arthritis Rheumatol

Shalev Rosenthal Y, Schwartz N, Sagy I, Pavlovsky L

doi: 10.1002/art.41946

PsoriasisPsoriatic Arthritis

A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation

J Am Acad Dermatol.

Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF

doi: 10.1016/j.jaad.2019.03.017.

Psoriasis

Reduced Risk of Mortality Associated With Systemic Psoriasis Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A Nested Case-Control Analysis

J Am Acad Dermatol.

Langley RG, Poulin Y, Srivastava B, Lafferty KP, Fakharzadeh S, Langholff W, Augustin M

doi: 10.1016/j.jaad.2020.08.032.

Rheumatoid Arthritis

Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease

Clin Rheumatol.

Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL

doi: 10.1007/

Psoriasis

Secukinumab treatment leads to normalisation of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: The PROSE study results

J Eur Acad Dermatol Venereol.

Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Kingo K, Szepietowski JC, Perrot JL, Cuccia A, Rissler M, Gathmann S, Sieder C, Orsenigo R, Jagiello P, Bachhuber T

doi: 10.1111/jdv.16632.

Juvenile Idiopathic ArthritisPsoriatic Arthritis

Risk of Hospitalized Serious Infection After Initiating Ustekinumab or Other Biologics for Psoriasis or Psoriatic Arthritis

Arthritis Care Res (Hoboken)

Jin Y, Lee H, Lee MP, Landon JE, Merola JF, Desai RJ, Kim SC

doi: 10.1002/acr.24630

Related content

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics

Safety of Systemic Agents for the Treatment of Pediatric Psoriasis

Psoriatic arthritis incidence among patients receiving biologic medications for psoriasis: A nested case control study

A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation

Reduced Risk of Mortality Associated With Systemic Psoriasis Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A Nested Case-Control Analysis

Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease

Secukinumab treatment leads to normalisation of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: The PROSE study results

Risk of Hospitalized Serious Infection After Initiating Ustekinumab or Other Biologics for Psoriasis or Psoriatic Arthritis